The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.33 as of 05 May 15:30
. The P/E Ratio of Bharat Immunological & Biological Corporation Ltd is 0 as of March 2024
.The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024
. The Market Cap of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of March 2024
.The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024
. The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .
About Bharat Immunological & Biological Corporation Ltd
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.
The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96.
The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.
About Remus Pharmaceuticals Ltd
Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad.
The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.
FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Remus Pharmaceuticals Ltd
Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Remus Pharmaceuticals Ltd?
Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Remus Pharmaceuticals Ltd is 831 Cr
What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Remus Pharmaceuticals Ltd?
The stock performance of Bharat Immunological & Biological Corporation Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Remus Pharmaceuticals Ltd?
As of May 5, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.33. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹705.75.
How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Remus Pharmaceuticals Ltd compare?
To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.